AGENUS INC — Director's Dealing 2010

Nov 3, 2010

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANTIGENICS INC /DE/ (AGEN)
CIK: 0001098972
Period of Report: 2010-11-01

Reporting Person: ARMEN GARO H (Chairman & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2010-11-01	Common Stock	J	11111	$0.99	Acquired	2245326	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5475372	Indirect

Footnotes

F1: Represents the issuance of stock for payment of 30% of Dr. Armen's base salary for the month of October 2010.

F2: Dr. Armen is trustee and has investment authority for the Garo Armen 2009 2 year GRAT and the Garo Armen 2009 4 year GRAT, each holding 1,607,183 and 2,336,246 shares of Antigenics Inc. common stock, respectively. Dr. Armen disclaims beneficial owenrship therein. Dr. Armen is the General Partner of Armen Partners LP. As of the date of this report Armen Partners owns a total of 1,507,667 shares of Antigenics Inc. common stock. Dr. Armen is also CEO, Chairman of the Board of Managers and a member of Antigenics Holdings LLC ("Holdings") which as of the date of this report owns 24,276 shares of Antigenics Inc. common stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Armen Partners and Holdings and disclaims beneficial ownership except to the extent of his pecuniary interest therein.